Literature DB >> 6725531

Modulation of immunologic responses in nontuberculous mycobacterial infections with indomethacin.

U G Mason, C H Kirkpatrick.   

Abstract

We have previously reported that impaired in vitro cellular immunity is a common finding in patients with nontuberculous mycobacterioses and that the subnormal responses may be improved by indomethacin. Subsequently, we have studied the in vivo effects of indomethacin on cell-mediated immune functions of four patients with Mycobacterium avium-intracellulare infections. Prior to treatment none of the patients had delayed cutaneous reactions to purified protein derivative (PPD) of the tubercle bacillus, and their lymphocytes had subnormal in vitro proliferation responses to tuberculins from M. tuberculosis and M. avium-intracellulare and to phytohemagglutinin. The administration of indomethacin reconstituted both the in vitro lymphocyte responses and delayed cutaneous hypersensitivity. We propose that the impairment of T-cell dependent immune functions is mediated by a suppressive factor (or factors) that is a metabolic product(s) of the cyclooxygenase pathway of arachidonic acid metabolism. Preferential inhibition of this pathway with indomethacin allows the expression of cell-mediated responses.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6725531     DOI: 10.1007/BF00915044

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  29 in total

Review 1.  Nontuberculous mycobacteria and associated diseases.

Authors:  E Wolinsky
Journal:  Am Rev Respir Dis       Date:  1979-01

2.  Importance of thymus-derived lymphocytes in cell-mediated immunity to infection.

Authors:  R J North
Journal:  Cell Immunol       Date:  1973-04       Impact factor: 4.868

3.  Transfer factor therapy in a patient with progressive primary tuberculosis.

Authors:  M E Whitcomb; R E Rocklin
Journal:  Ann Intern Med       Date:  1973-08       Impact factor: 25.391

4.  Partial reversal of the cellular immune defect in common variable immunodeficiency with indomethacin.

Authors:  J S Goodwin; A D Bankhurst; S A Murphy; D S Selinger; R P Messner; R C Williams
Journal:  J Clin Lab Immunol       Date:  1978-11

5.  Cell-mediated immunity in anergic patients with pulmonary tuberculosis.

Authors:  D N McMurray; A Echeverri
Journal:  Am Rev Respir Dis       Date:  1978-11

6.  Effects of arachidonic acid and other unsaturated fatty acids on mitogenesis in human lymphocytes.

Authors:  J P Kelly; C W Parker
Journal:  J Immunol       Date:  1979-04       Impact factor: 5.422

7.  Treatment of disease due to Mycobacterium intracellulare.

Authors:  P T Davidson; V Khanijo; M Goble; T S Moulding
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

8.  Mediation of macrophage collagenase production by 3'-5' cyclic adenosine monophosphate.

Authors:  J B McCarthy; S M Wahl; J C Rees; C E Olsen; L Sandberg; L M Wahl
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

9.  Clinical and immunologic response to antigen-specific transfer factor in drug-resistant infection with Mycobacterium xenopi.

Authors:  J M Dwyer; B J Gerstenhaber; K J Dobuler
Journal:  Am J Med       Date:  1983-01       Impact factor: 4.965

10.  Demonstration in tissue culture of lymphocyte-mediated immunity to tuberculosis.

Authors:  R J Patterson; G P Youmans
Journal:  Infect Immun       Date:  1970-06       Impact factor: 3.441

View more
  2 in total

1.  Prospective study of mycobacterial infections in patients with cystic fibrosis.

Authors:  L Hjelte; B Petrini; G Källenius; B Strandvik
Journal:  Thorax       Date:  1990-05       Impact factor: 9.139

2.  Indomethacin-sensitive monocyte killing defect in a child with disseminated atypical mycobacterial disease.

Authors:  D Ridgway; L J Wolff; M Wall; M S Borzy; C H Kirkpatrick
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.